{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:03Z","timestamp":1753891863234,"version":"3.41.2"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background and objective<\/jats:title><jats:p>Assessing the impact of chemotherapy-induced nausea and vomiting (CINV) on the quality of life (QoL) of cancer patients is critical. However, there is a dearth of specialized assessment tools designed specifically for pediatric cancer patients. The aim of this study was to develop and validate the Pediatrics Functional Living Index-Emesis (PFLIE) as a patient-reported outcome measure (PROM) to assess the impact of CINV on QoL in pediatric patients. This study was approved by the Institutional Review Board of Sun Yat-sen University Cancer Center (Approval No. B2021-113-01) and was conducted in accordance with the Declaration of Helsinki.\u200b<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>The reliability, content validity, structural validity, and concurrent validity of the PFLIE were assessed through two rounds of Delphi expert consultation and a questionnaire survey of 90 pediatric cancer patients receiving chemotherapy at a tertiary care hospital cancer center in China.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The PFLIE consists of two domains: nausea (10 items) and vomiting (10 items). The content validity index (CVI) for both the nausea and vomiting domains was 0.933. The Cronbach\u2019s alpha coefficients for the total scale, nausea domain, and vomiting domain were 0.964, 0.928, and 0.943, respectively. Item-domain correlations were stronger for the PFLIE (r = 0.678-0.882) across domains compared to across-domain correlations (r = 0.493-0.780), suggesting that the PFLIE has acceptable construct validity. In addition, the PFLIE demonstrated acceptable concurrent validity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The validity and reliability of the Chinese version of the PFLIE are reliable and valid. The tool can help healthcare providers effectively identify and manage CINV symptoms, thereby improving the QoL of pediatric cancer patients. In low- and middle-income countries (LMICs) with limited resources, PFLIE can be used to improve the management of CINV and to ensure that pediatric cancer patients receive adequate care despite inadequate healthcare infrastructures. The tool can be used to improve the management of CINV and to ensure that pediatric cancer patients receive adequate care despite inadequate healthcare infrastructures.\u200b<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1573996","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T05:22:25Z","timestamp":1750742545000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of the Pediatrics Functional Living Index\u2014Emesis scale"],"prefix":"10.3389","volume":"15","author":[{"given":"Lili","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanqi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jieru","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feifei","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruiqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","article-title":"Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: A systematic review","volume":"99","author":"Sommariva","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-021-01898-9","article-title":"The efficacy of aprepitant in salvage treatment of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy for patients with gastrointestinal cancer","volume":"26","author":"Gong","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-017-0228-2","article-title":"Management of chemotherapy-induced nausea and vomiting in pediatric patients","volume":"19","author":"Navari","year":"2017","journal-title":"Paediatr Drugs"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedneo.2021.12.010","article-title":"A scoping review of nausea, vomiting and retching measurement methods in children with cancer","volume":"63","author":"Ewig","year":"2022","journal-title":"Pediatr Neonatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3384-y","article-title":"2016 updated MASCC\/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children","volume":"25","author":"Dupuis","year":"2017","journal-title":"Support Care Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.v64.10","article-title":"Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update","volume":"64","author":"Patel","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11912-019-0840-0","article-title":"Latest update on prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients","volume":"21","author":"Sherani","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v8.14","article-title":"Analysis of concordance with antiemetic guidelines in pediatric, adolescent, and young adult patients with cancer using a large-scale administrative database","volume":"8","author":"Bun","year":"2019","journal-title":"Cancer Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1177\/1043454219900467","article-title":"Nausea in numbers: electronic medical record nausea and vomiting assessment for children with cancer","volume":"37","author":"Evans","year":"2020","journal-title":"J Pediatr Oncol Nurs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4257-3","article-title":"Perspectives of children, family caregivers, and health professionals about pediatric oncology symptoms: a systematic review","volume":"26","author":"Cheng","year":"2018","journal-title":"Support Care Cancer"},{"key":"B11","article-title":"Chemotherapy-induced nausea and vomiting: optimizing prevention and management","volume":"5","author":"Rao","year":"2012","journal-title":"Am Health Drug Benefits"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/BF00434947","article-title":"Quality of life consequences of chemotherapy-induced emesis","volume":"1","author":"Lindley","year":"1992","journal-title":"Qual Life Res"},{"key":"B13","article-title":"Assessing the impact of chemotherapy-induced nausea and vomiting on patients\u2019 daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall","volume":"11","author":"Martin","year":"2003","journal-title":"Support Care Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/1078155221998447","article-title":"Assessing the impact of chemotherapy-induced nausea and vomiting on patients\u2019 quality of life: An Arabic version of the Functional Living Index-Emesis","volume":"28","author":"Alhammad","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-9957-9","article-title":"A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy","volume":"113","author":"Yeo","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"B16","doi-asserted-by":"publisher","first-page":"104876","DOI":"10.1016\/j.nedt.2021.104876","article-title":"Development of the competency assessment scale for clinical nursing teachers: Results of a Delphi study and validation","volume":"101","author":"He","year":"2021","journal-title":"Nurse Educ Today"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S97695","article-title":"Chemotherapy-induced nausea and vomiting: exploring patients\u2019 subjective experience","volume":"9","author":"Salihah","year":"2016","journal-title":"J Multidiscip Healthc"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7001.376","article-title":"Consensus methods for medical and health services research","volume":"311","author":"Jones","year":"1995","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v127.9","article-title":"Validation of the caregiver Pediatric Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events measure","volume":"127","author":"Reeve","year":"2021","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa016","article-title":"Validity and reliability of the pediatric patient-reported outcomes version of the common terminology criteria for adverse events","volume":"112","author":"Reeve","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/PTS.0000000000000733","article-title":"The patient safety culture scale for Chinese primary health care institutions: development, validity and reliability","volume":"17","author":"Cheng","year":"2021","journal-title":"J Patient Saf"},{"key":"B22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1186\/s12885-022-09995-2","article-title":"Translation and validation of M.D. Anderson Symptom Inventory-Thyroid Cancer module in Chinese thyroid cancer patients: a cross-sectional and methodological study","volume":"22","author":"Hu","year":"2022","journal-title":"BMC Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12955-022-01970-6","article-title":"Development and validation of the psoriasis scale among the system of quality of life instruments for chronic diseases QLICD-PS (V2.0)","volume":"20","author":"Liu","year":"2022","journal-title":"Health Qual Life Outcomes"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.314.7080.572","article-title":"Statistics notes: Cronbach\u2019s alpha","volume":"314","author":"Bland","year":"1997","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.5116\/ijme.4dfb.8dfd","article-title":"Making sense of Cronbach\u2019s alpha","volume":"2","author":"Tavakol","year":"2011","journal-title":"Int J Med Educ"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215295","article-title":"Single center experience on efficacy and safety of Aprepitant for preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric Hodgkin Lymphoma","volume":"14","author":"Giagnuolo","year":"2019","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/0300060518765324","article-title":"Acute chemotherapy-induced nausea and vomiting in children with cancer: Still waiting for a common consensus on treatment","volume":"46","author":"Ruggiero","year":"2018","journal-title":"J Int Med Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3866-6","article-title":"Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses","volume":"26","author":"Clark-Snow","year":"2018","journal-title":"Support Care Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.9.1221","article-title":"Development and validation of the pediatric nausea assessment tool for use in children receiving antineoplastic agents","volume":"26","author":"Dupuis","year":"2006","journal-title":"Pharmacotherapy"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/NCC.0b013e3182281493","article-title":"Nausea and vomiting perspectives among children receiving moderate to highly emetogenic chemotherapy treatment","volume":"35","author":"Rodgers","year":"2012","journal-title":"Cancer Nurs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12955-023-02205-y","article-title":"Development and validation of the systemic lupus erythematous scale amongst the system of quality of life instruments for chronic diseases QLICD-SLE (V2.0)","volume":"21","author":"Liu","year":"2023","journal-title":"Health Qual Life Outcomes"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1573996\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T05:22:25Z","timestamp":1750742545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1573996\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":31,"alternative-id":["10.3389\/fonc.2025.1573996"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1573996","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,6,24]]},"article-number":"1573996"}}